cyclophosphamide

Cyclophosphamide 是一种烷化剂，具有抗肿瘤及免疫抑制活性，用于治疗多种癌症。

Cyclophosphamide hydrate 是一种 DNA 烷化剂，一种 DNA 合成抑制剂。Cyclophosphamide hydrate 具有抗肿瘤活性、免疫抑制活性等。

Sodium 2-mercaptoethanesulfonate (Uromitexan) 是一种抗氧化剂，具有细胞保护作用。它可用于减轻由环磷酰胺引起的出血性膀胱炎。它广泛用作抗化学疗法毒性的全身保护剂。

4-oxo Cyclophosphamide is an inactive metabolite of the alkylating agent cyclophosphamide .1,2It is formed from cyclophosphamide through a 4-hydroxycyclophosphamide intermediate by aldehyde dehydrogenases.2 1.Struck, R.F., Kirk, M.C., Mellett, L.B., et al.Urinary metabolites of the antitumor agent cyclophosphamideMol. Pharmacol.7(5)519-529(1971) 2.de Jonge, M.E., Huitema, A.D.R., Rodenhuis, S., et al.Clinical pharmacokinetics of cyclophosphamideClin. Pharmacokinet.44(11)1135-1164(2005)

4-hydroperoxy cyclophosphamide (4-OOH-CY) 是 Cyclophosphamide 的活性代谢物，可诱导肝毒性。4-Hydroperoxy cyclophosphamide 可增加谷丙转氨酶和天冬氨酸转氨酶水平，增强炎症因子和氧化指标，抑制氧化还原酶活性。4-hydroperoxy cyclophosphamide 可用于研究癌症和自身免疫疾病。

Cyclophosphamide-d4 是 Cyclophosphamide 的氘代化合物。Cyclophosphamide 的 CAS 号为 50-18-0。Cyclophosphamide 是一种烷化剂，具有抗肿瘤及免疫抑制活性，用于治疗多种癌症。

Cyclophosphamide-d8 是 Cyclophosphamide 的氘代化合物。Cyclophosphamide 的 CAS 号为 50-18-0。Cyclophosphamide 是一种烷化剂，具有抗肿瘤及免疫抑制活性，用于治疗多种癌症。

Ifosfamide (NSC-109724) 是一种烷化剂，具有抗肿瘤活性。它烷基化并形成 DNA 交联，从而防止 DNA 链分离和 DNA 复制。它是一种前药，必须通过肝微粒体酶的羟基化来激活。

Cofpropamine 作为一种源自咖啡因的衍生物，能抑制多聚腺苷酸化。在大鼠的佐剂性关节炎和小鼠的胶原性关节炎模型中，它能增强Cyclophosphamide的抑制效果。

YHS-12是一种电离性阳离子脂质（pKa = 6.506），可在脂质纳米粒子（LNPs）中封装并传递siRNA和mRNA，用于体外及体内应用。这些LNPs由YHS-12与靶向巨噬细胞的肽CRVLRSGSC组成，主要用于封装针对甲氧西林抗性金黄色葡萄球菌（MRSA）的嵌合抗原受体mRNA以及针对caspase-11的siRNA。此外，这些LNPs能够增强RAW 264.7巨噬细胞及原代小鼠骨髓来源巨噬细胞（BMDMs）清除MRSA的效能。通过静脉注射这些LNPs于环磷酰胺诱导的免疫抑制小鼠的脓毒症模型中，可以显著降低血液中的细菌数量并提高生存率。

GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder. GR-203040 is a selective NK1 receptor antagonist.

L-Ifosfamide is nitrogen mustard, a chemotherapeutic antineoplastic, and more precisely an alkylating agent structural analog of cyclophosphamide with respect to which presents some differences regard to the antitumor activity and spectrum.

Alcophosphamide is a urinary metabolite of cyclophosphamide which may be used in proteomics research.

Phosphoramide mustard cyclohexanamine（磷酰胺氮芥环己胺盐）是cyclophosphamide的活性代谢物，是一种交联DNA链的烷基化剂，组织细胞分裂并导致细胞死亡，具有抗肿瘤活性。

Carboxyphosphamide is an inactive metabolite of the alkylating agent cyclophosphamide .1It is formed from cyclophosphamideviaoxidation of the intermediate metabolite aldophosphamide by aldehyde dehydrogenase. 1.Manthey, C.L., and Sladek, N.E.Kinetic characterization of the catalysis of activated cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenasesBiochem. Pharmacol.37(14)2781-2790(1988)

Phosphoramide mustard 是环磷酰胺的毒性代谢物物，具有抗癌活性且对卵巢具有毒性，可诱导 DNA 损伤。

ERCC1-XPF-IN-1 是有效的、高亲和力的 ERCC1-XPF 抑制剂 (IC50: 0.49 μM)。ERCC1-XPF-IN-1 能够抑制 CPDs 的去除，降低环磷酰胺对结直肠癌细胞的毒性，提高了 UV 辐射的细胞毒性作用，阻碍 DNA 修复。

Mafosfamide is a synthetic oxazaphosphorine derivative with antineoplastic properties. Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis. Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis.

Mafosfamide sodium is a synthetic oxazaphosphorine derivative with antineoplastic properties. Mafosfamide sodium alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis. Although closely related to cyclophosphamide, Mafosfamide sodium, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, Mafosfamide sodium is potentially useful in the intrathecal treatment of neoplastic meningitis.

CI-898 HCl is a lipophilic antifolate inhibitor of dihydrofolate reductase (DHFR). It has enhanced binding to DHFR in the presence of the cofactor NADPH. Cl-898 HCl inhibits cell growth and halts the cell cycle at the G1 S phase in L1210 mouse lymphocytic leukemia cells and is active against methotrexate-resistant cancer cell lines. It also enhances the activity of doxorubicin, cyclophosphamide, and 6-thioguanine (6-TG) in mice with advanced stage P338 leukemia.

RKS262 is a specific cyclin CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment.